CURRICULUM VITAE

Name: Jack A. Taylor, M.D., Ph.D.

Date and Place of Birth: May 3, 1955 Merrill, Wisconsin

Citizenship: United States

Education:

1977	B.A.	(Biology) <u>cum laude</u> , Carleton College
		Northfield, Minnesota
1978-80		Ph.D. Candidate, Population Genetics and Evolutionary Biology
		University of Arizona, Tucson, Arizona
1984	M.D.	University of Wisconsin School of Medicine
		Madison, Wisconsin
1993	Ph.D.	Department of Epidemiology, University of North Carolina, Chapel Hill,
		North Carolina

Board Certification:

National Board of Medical Examiners #292343

Medical license, North Carolina #30868

American Board of Preventive Medicine:

Specialist in Public Health and General Preventive Medicine

Brief Chronology of Employment:

1976	Environmental Biologist, Water Treatment Plant, Ward Paper Company
1977-78	Water Quality Researcher, Wisconsin Department of Natural Resources
1978-80	Graduate Teaching Assistant, University of Arizona
1984-85	Resident, Department of Radiology, Michigan State University
1985-87	Resident, Preventive Medicine, University of North Carolina
1985-88	USPHS-NIH Epidemiology Training Program, NIEHS
1988-95	Senior Clinical Researcher, Epidemiology Branch, NIEHS
1995-date	Tenure Appointment, Senior Investigator, Epidemiology Branch, NIEHS
1997-date	Head, Molecular & Genetic Epidemiology Section, Laboratory of Molecular Carcinogenesis, NIEHS

University Affiliations:

Adjunct Professor, Department of Epidemiology, University of North Carolina

Adjunct Professor, Department of Medicine, University of North Carolina

Adjunct Professor, Lineberger Comprehensive Cancer Center, University of North Carolina

Adjunct Professor, Department of Medicine, Duke University

Honors & Other Special Scientific Activities:

Summer Research Fellowship, University of Wisconsin School of Medicine, 1981 Dean's Award for Academic Achievement, U. W. Medical School 1982 and 1983 Fellow, Conte Institute for Environmental Health

NCI Ad Hoc Study Section on Genetic Alterations in Bladder Carcinogenesis, 1988 NRC Committee on DoE Radiation Epidemiological Research Program, 1992 - 1994 Reviewer for:

British J. Cancer

Cancer Research

Carcinogenesis

Environmental Research

Environmental and Molecular Mutagenesis

International J. Cancer

Journal of the National Cancer Institute

Molecular Carcinogenesis

Molecular Medicine

Obstetrics and Gynecology

Oncogene

Pharmacogenetics

National Toxicology Program Chemical Nominations Committee

NCI *ad hoc* committee on molecular-epidemiologic enhancements to the NCI Prostate, Lung, Colorectal (PLCO) Screening Trial.

NIEHS Interdisciplinary Research Awards

1993-94: Genetic susceptibility to spontaneous abortion

1994-95: Genetic and environmental risk factors for myelodysplasia

1994-95: Reproductive failure associated with mutation of the ER gene

1998-01: Functional analysis of human DNA metabolic genes and clinically important mutant alleles in bacteria & yeast

U.S. Public Health Service Commendation Medal 1994: "For development of a highly creative program of epidemiologic research that incorporates molecular genetic markers in studies of environmental causes of human disease."

NIEHS Institutional Review Board 1995-2003

Acting Clinical Director, NIEHS 12/95-2/96

NCI Committee on Promotions, ad hoc member, 1997

Acting Chair, NIEHS Institutional Review Board 8/98-11/98

NIEHS Executive Committee, 1997-2001

NIH Merit Award 1997: "For development of the Environmental Genome Project"

NIH Central Tenure Committee, Ad hoc member 1997-2003

Vice Chair, NIEHS Institutional Review Board 1998-2003

Chair, NIEHS Environmental Genomics Faculty 1999 – 2003

Current Committees and Journal Board Activities

Editorial Review Board Environmental Health Perspectives

Associate Editor: Cancer Epidemiology, Biomarkers, and Prevention

Board of Governors, NIH Center for Inherited Disease Research, 1997-present

American Cancer Society Biospecimen Advisory Board, 2002-present

NIEHS Committee on Tenure and Promotions 2002-present

NIH Central Tenure Committee 2003-present

Funded Grants:

Examination of genetic alterations in preneoplastic and neoplastic lesions of the lung from uranium miners. Consultant. DOE. St. Mary's Hospital and Medical Center, Dr. Marshall Anderson PI, \$506,393 1994-97.

Breast Cancer SPORE. Consultant, Molecular Epidemiology Program. P50CA58223-03 University of North Carolina, Dr. Edison Liu PI, \$1,500,000 per year 1992-95

Environmentally induced bladder cancer: a genetic study. Consultant. IR01ES06094 Salk Institute, Dr. S. Sukumar PI, \$50,000 per year 1992-1994

Nutritional biochemistry and epidemiology of cancer training grant. T32CA72319-01A1 Consultant. University of North Carolina, Dr. Lenore Kohlmeier PI, \$88,856 1997-02, renewal \$1.4M 2002-07

Environmental Health and Susceptibility Center Grant. U. North Carolina, Affiliate Member, Genetic Susceptibility Core, \$700,000 per year 2001-4

Department of Energy Prostate Cancer Consortium. PI Genetic Susceptibility Project, and Coinvestigator Proteomics Project. Dr. James Mohler Consortium PI \$9,997,794, 2003-2008.

Publications:

- 1 Rosenzweig MD and **Taylor JA**. Speciation and diversity in Ordovician invertebrates: filling niches quickly and carefully. Oikos <u>35</u>:236-243, 1980.
- 2 **Taylor JA** and Davis JP. Evidence for clustering of amyotrophic lateral sclerosis in Wisconsin. J. Clin. Epidemiol. 1989; 42:569-575.
- 3 **Taylor JA**. Oncogenes and their application in epidemiologic studies. Am. J. Epidemiol. 1989; 130:6-13.
- **Taylor JA**. Epidemiologic Studies of the Molecular Genetics of Cancer. Birth Defects 1989; 25:83-93.
- 5 Sienko DG, Davis JP, **Taylor JA**, Brooks BR. Amyotrophic lateral sclerosis: A case-control study of a cluster in a small Wisconsin Community. Arch. Neurol. 1990; 47:38-41.
- 6 **Taylor JA**. Epidemiologic Evidence of Genetic Susceptibility to Cancer. Birth Defects 1990; 26:113-127.
- 7 Liu YH, **Taylor JA**, Linko P, Lucier GW, and Thompson CL. Glutathione S-transferase mu in Human Lymphocyte and Liver: Role in Modulating Formation of Carcinogen-Derived DNA Adducts. Carcinogenesis 1991; 12:2269-2275.
- 8 **Taylor JA**, Li Y, You M, Wilcox AJ, Liu E. B region variant of the estrogen receptor gene. Nucleic Acids Res. 1992; 20:2895.

Publications (continued):

- Bell DA, Thompson CL, **Taylor JA**, et al. Genetic monitoring of human polymorphic cancer susceptibility genes by polymerase chain reaction: application to glutathione transferase mu. Environ. Health Persp. 1992; 98:113-117.
- 10 **Taylor JA**, Sandler DP, Bloomfield CD, et al. *ras* oncogene activation and occupational exposures in acute myeloid Leukemia. J. Natl. Cancer Inst. 1992; 84:1626-1632.
- Piegorsch W, **Taylor JA**. Statistical methods for assessing environmental effects on human genetic disorders. Environmetrics 1992; 3:369-384.
- Bell DB, **Taylor JA**, Paulson DF, Robertson JL, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: A common inherited defect of the carcinogen-metabolism gene Glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J. Natl. Cancer Inst. 1993; 85:1159-1164.
- 13 **Taylor JA**, Wilcox AJ, Bowes WA, Li Y, Liu ET, You M. Risk of miscarriage and a common variant of the estrogen receptor gene. Am. J. Epidemiol. 1993; 137:1361-1364.
- **Taylor JA**, Bell DA, Nagorney D. L-myc proto-oncogene alleles and susceptibility to hepatocellular carcinoma. Int. J. Cancer 1993; 54:927-930.
- Bell DB, **Taylor JA**, Butler MA, Stephens E, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14:1689-1692.
- Schweikl H, **Taylor JA**, Kitereewan S, Linko P, Nagorney D, Goldstein JA. Expression of CYP1A1 and CYP 1A2 genes in human liver. Pharmacogenetics 1993; 3:239-249.
- Piegorsch W, Weinberg CR, **Taylor JA**. Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. Statistics in Medicine 1994; 13:153-162.
- **Taylor JA**, Watson MA, Devereux TR, Michels R, Saccomanno G, Anderson M. P53 mutation hotspot in radon-associated lung cancer. Lancet 1994; 343:86-87.
- 19 Stephens EA, **Taylor JA**, Kaplan N, Hsieh, LL, Lucier GW, Bell DA. Ethnic variation in the CYP2E1 gene: Polymorphism analysis of 685 African-Americans, European-Americans and Taiwanese indicates the presence of a unique haplotype in Taiwanese. Pharmacogenetics 1994; 4:185-192.
- 20 Packenham JP, **Taylor JA**, White CW, Anna CH, Barrett JC, Devereux TR. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non small cell lung cancers. Clinical Cancer Res. 1995; 1:687-690.
- Lancaster JM, Brownlee HA, Wiseman RW, **Taylor JA**. P53 polymorphism in ovarian and bladder cancer. Lancet (letter) 1995; 346:182.

Publications (continued):

- McDonald JW, **Taylor JA**, Watson MA, Saccomanno G, Devereux TR. p53 and K-ras in radon-associated lung adenocarcinoma. Cancer Epi Biomarkers Prev. 1995; 4:791-793.
- Packenham JP, **Taylor JA**, Anna CH, White CM, Devereux TR. Homozygous deletions but not sequence mutations in coding regions of p15 or p16 in human primary bladder tumors Mol. Carcinogenesis 1995; 14:147-151.
- Hirvonen A, **Taylor JA**, Wilcox AJ, Berkowitz G, Schachter B, Chaparro C, Bell DA. Xenobiotic metabolism genes and the risk of recurrent miscarriage. Epidemiology 1996; 7:206-208
- Devereux TR, **Taylor JA**, Barrett JC. Molecular mechanisms of lung cancer: Interaction of environmental and genetic factors. Chest 1996; 109:14S-19S.
- Taylor JA, Li Y, Mason T, Mettlin C, Vogler WJ, Maygarden S, Liu E. p53 mutations in bladder tumors from arylamine-exposed workers. Cancer Res. 1996; 55:294-298
- 27 Chen H, Sandler D, **Taylor JA**, Watson M, Shore DL, Liu E, Bell DA. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (*GSTTI*) gene defect. Lancet 1996; 347:295-297.
- Lancaster JM, **Taylor JA**, Brownlee HA, Bell DA, Berchuck A, Wiseman RW. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinogenesis 1996; 17:160-162.
- Taylor JA, Hirvonen A, Watson, M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996; 56:4108-4110
- Tomatis L, Huff J, Hertz-Picciotto I, Sandler D, Bucher J, Boffetta P, Axelson O, Blair A, **Taylor J**, Stayner L, Barrett JC. Avoided and avoidable risks of cancer. Carcinogenesis 1997; 18:97-105.
- 31 Bell DA, **Taylor JA**. Genetic analysis of complex diseases. Science [Technical Comments] 1997; 275:1327-1328.
- London SJ, Lehman TA, **Taylor JA**. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 1997; 57:5001-5003.
- Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Robertson C, Mohler J, Bell DA. The role of N-acetylation polymorphisms in smoking-associated bladder cancer, evidence of a gene-gene-environment 3-way interaction. Cancer Res 1998; 58:3603-3610
- Lancaster, J. M., Berchuck, A., Carney, M. E., Wiseman, R., and **Taylor JA**, Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. Br J.Cancer 1998; 78: 277.
- 35 Slebos RJC, Resnick MA, **Taylor JA**. Inactivation of the p53 tumor suppressor gene via a novel Alu rearrangement. Cancer Research 1998; 58:5333-5336

Publications (continued):

- Hulla, JE, Miller, MS, **Taylor JA**, Hein DW, Furlong, CE, Omiecinski, CJ, and Kunkel, TA. Symposium Overview, The Role of Genetic Polymorphism and Repair Deficiencies in Environmental Disease. Toxicol. Sci. 1999; 47:135-143.
- Wilcox AJ, **Taylor JA**, Sharp RR, London SJ, Genetic determinism and over-protection of human subjects. Nature Genetics 1999; 21: 36
- Burroughs KD, Dunn SE, Barrett JC, **Taylor JA.** IGF-I: A key regulator of human cancer risk? [invited editorial] J. Natl. Cancer Inst. 1999; 91:579-81
- Lunn RM, Bell DA, Mohler JL, **Taylor JA**. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999; 20:1727-1731
- 40 Blazer DG, Umbach DM, Bostick RM, **Taylor JA.** Vitamin D receptor polymorphisms and prostate cancer. Mol. Carcinogenesis 2000; 27:18-23
- 41 Slebos RJC, Hoppin JA, Tolbert PE, Holly EA, Brock J, Zhang RH, Bracci PM, Foley J, Stockton P, McGregor LM, Flake G, **Taylor JA.** K-ras and p53 in pancreatic cancer: Association with medical history, histopathology and environmental exposures in a population-based study. Cancer Epidemiology Biomarkers and Prevention 2000; 9:1223-1232
- 42. Stern MC, Umbach DM, van Gils CH, Lunn RM, **Taylor JA.** DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer Epidemiology Biomarkers and Prevention 2001; 10:125-131
- 43 Stern, MC, Umbach DM, Yu MC, London SJ, Zhang Z-Q, **Taylor JA**. Hepatitis B, Aflatoxin B1, and p53 codon p53 codon 249 mutation hepatocellular carcinomas from Guangxi, People's Republic of China. Cancer Epidemiology Biomarkers and Prevention 2001; 10:617-627
- Slebos RJC, **Taylor**, **JA**. A novel host cell reactivation assay to assess homologous recombination capacity in human cancer cell lines. Biochemical and Biophysical Research Communications 2001; 281:212-219
- Devereux TR, Stern MC, Flake GP, Yu MC, London SJ, **Taylor JA** CTNNB1 mutations and β-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1. Mol. Carcinogenesis 2001; 31:68-73.
- Hoppin JA, Tolbert PE, **Taylor JA**, Schroeder JC, Holly EA. Potential for selection bias with tumor tissue retrieval for molecular epidemiology studies. Ann Epidemiol 2002; 12:1-6
- 47 Stern MC, Johnson LR, Bell DA, **Taylor JA**. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk. Cancer Epidemiology Biomarkers and Prevention. 2002; 11:1004-1011.
- Thompson TE, Rogan PK, Risinger JI, **Taylor JA.** Splice variants, but not mutations, of DNA Polymerase β are common in bladder cancer. Cancer Research 2002; 62:3251-3256.
- 49 vanGils CH, Conway K, Li Y, **Taylor JA.** *HRAS1* variable number tandem repeat polymorphism and risk of bladder cancer. International J. Cancer 2002; 100:414-8.

- vanGils CH, Bostick RM, Stern MC, **Taylor JA**. Differences in base excision repair capacity may modulate the effect of dietary antioxidant intake on prostate cancer risk: an example of polymorphisms in the XRCC1 gene, Cancer Epidemiology Biomarkers and Prevention 2002; 11:1279-84.
- 51 Stern MC, Umbach DM, Lunn RM, **Taylor JA.** DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms and bladder cancer risk. Cancer Epidemiology Biomarkers and Prevention. 2002; 11:939-943
- 52 Slebos JC, Oh DS, Umbach DM, **Taylor JA**. Mutations in tetranucleotide repeats following DNA damage depend on repeat sequence and carcinogenic agent. Cancer Research 2002; 62:6052-60
- Engel LS, Taioli E, Pfeiffer R, Garcia-Closas M, Marcus PM, Lan Q, Boffetta P, Vineis P, Autrup H, Bell DA, Branch RA, Brockmoller J, Kaly AK, Heckbert SR, Kalina I, Kang DH, Katoh T, Lafuente A, Lin HJU, Romkes M, **Taylor JA**, Rothman N. Pooled analysis and meta-analysis of GSTM1 and bladder cancer: A HuGE Mini-Review. Am J Epidemiol 2002; 156:95-109.
- Jugessur A, Lie RT, Wilcox AJ, Murray JC, Taylor JA, Saugstad OD, Vindenes H, Abyholm F. Variants of developmental genes (*TGFα*, *TGFβ3*, and MSXI) and their associations with facial clefts A case-parent triad analysis. Genetic Epidemiology 2003 24:230-9
- Jugessur A, Wilcox AJ, Lie RT, Murray JC, **Taylor JA**, Ulvik A, Vindenes H, Abyholm F. Exploring the effects of methylenetetrahydrofolate reductase gene variants C677T and A1298C on the risk of orofacial clefts in 261 Norwegian case-parent triands. Am. J. Epidemiology 2003 157:1083-91
- Dunson DB, Watson M, **Taylor JA**. Bayesian latent variable models for median regression on multiple outcomes. Biometrics 2003 59:296-304
- Jin YH, Clark AB, Slebos RJC, Al-Refai H, **Taylor JA**, Kunkel TA, Resnick MA, Gordenin DA. Cadmium is a mutagen that acts by inhibiting mismatch repair. Nature Genetics 2003 34:329-9.
- 58 Kamel F, Umbach DM, Lehman TA, Park LP, Munsat TL, Shefner JM, Sandler DP, Hu H, **Taylor JA**. Amyotrophic Lateral Sclerosis, Lead, and Genetic Susceptibility: Polymorphisms in the δ-Aminolevulinic Acid Dehydratase and Vitamin D Receptor Genes. Environmental Health Perspectives 2003 111:1335-9
- Jugessur A, Lie RT, Wilcox AJ, Murray JC, Taylor JA, Saugstad OD, Vindenes HA, Abyholm FE Cleft Palate, Transforming Growth Factor Alpha Gene Variants, and Maternal Exposures: Assessing Gene-Environment Interactions in Case-Parent Triads. Genetic Epidemiology 2003 25:367-74.
- Cooper GS, Treadwell EL, Dooley MA, St. Clair EW, Gilkeson GS, Taylor JA. N-Acetyl Transferase Genotypes in Relation to Risk of Developing Systemic Lupus Erythematosus. J Rheum 2004; 31:76-80
- Schroeder JC, Conway K, Li Y, Mistry K, Bell DA, **Taylor JA**. P53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors. Cancer Research 2003 63:7530-8

- 62 Slebos RJC, Umbach DM, Sommer CA, Horner GA, Choi JY, **Taylor JA** Analytical and statistical methods to evaluate microsatellite allelic imbalance in small amounts of DNA. Lab. Invest. 2004 84:648-57
- 63 Li L, Umbach DM, Terry P, **Taylor JA**. Application of the GA/KNN method to SELDI proteomics data. Bioinformatics 2004 20:1638-40
- 64 Slebos RJC, Little RE, Umbach DM, Antipkin Y, Zadaorozhnaja TD, Mendel NA, Sommer CA, Conway K, Parrish E, Gulino S, **Taylor JA**. Mini- and microsatellite mutations in children from Chernobyl accident cleanup works. Mut. Research 2004 559:143-51
- Terry PD, Kamel F, Umbach DM, Lehman TA, Hu H, Sandler DP, **Taylor JA** VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS) J. Neurogenetics 2004 18:429-34
- Terry PD, Umbach DM, **Taylor JA.** No association between SOD2 or NQO1 genotypes and risk of bladder cancer. Cancer Epidemiology Biomarkers and Prevention 2005 14:753-4
- 67 Slebos RJC, Livanos E, Yim H-W, Randell SH, Parsons AM, Detterbeck FC, Rivera MP, **Taylor JA**. Chromosomal abnormalities in bronchial epithelium from smokers, non-smokers and lung cancer patients. Cancer Genetics and Cytogenetics. 2005 159:137-42
- Kamel F, Umbach DM, Hu H, Munsat TL, Shefner JM, **Taylor JA**, Sandler DP. Lead exposure as a risk factor for amyotrophic lateral sclerosis. Neurodegener Dis 2005 2:195-201
- Dunson DB, **Taylor JA.** Approximate Bayesian Inference for Quantiles. J. Nonparametric Statistics 2005 17:385-400.
- Taylor JA, Xu ZL, Kaplan NL, Morris RW. How well do HapMap haplotypes identify common haplotypes of genes? A comparison with haplotypes of 334 genes resequenced in the Environmental Genome Project. Cancer Epidemiology Biomarkers and Prevention. 2006 15:133-7
- 71 Terry PD, Umbach DM, **Taylor JA**. APE1 genotype and risk of bladder cancer: Evidence for effect modification by smoking. Int J Cancer 2006 31:516-8
- Stern MC, Conway K, Li Y, Mistry K, **Taylor JA.** DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer. Molecular Carcinogenesis 2006 45:715-719.
- Yim HW, Slebos RJC, Randell SH, Umbach DM, Parsons AM, Rivera MP, Detterbeck FC, **Taylor JA.** Smoking is associated with increased telomerase activity in short-term cultures of human bronchial epithelial cells. In press: Cancer Letters.
- Flake GP, Rivera MP, Funkhouser WK, Slebos RJC, Maygarden SJ, Meadows KL, Long EH, Stockton PS, Jones TC, **Taylor JA**. Detection of pre-invasive lung cancer: Technical aspects of the LIFE Project. In press: Toxicologic Pathology

Book Chapters

- 1. Zhang, Z-F, Cordon-Cardo C, Rothman N, **Taylor JA**. Methodological issues in the use of tumor markers in cancer epidemiology. In: Application of Biomarkers in Cancer Epidemiology, Toniolo, Boffetta et al eds, 1997, IARC, Lyon
- 2. Stern MC, Koper NP, **Taylor JA**. Molecular Epidemiology. In: Introduction to Biochemical Toxicology. Hodgson and Smart eds, 2000.

Letters:

- 1. **Taylor JA**. Cone loss of the week. Science 1990; 247:270-271.
- 2. Taylor JA, Sandler DP, Shore DL. Re: Acute Myelogenous Leukemia. JNCI 1993; 85:921.
- 3. **Taylor JA**, Anderson M. Re: p53 mutation hotspot in radon-associated lung cancer. Lancet 1994; 343:1158-1159
- 4. **Taylor JA**, Wilcox AJ. Re: Risk of miscarriage and a common variant of the estrogen receptor gene. Am. J. Epidemiol. 1994; 140:1145

Conference Chair or Organizer

American Association for Cancer Research Program Committee 1997, 2000, 2001
Conference Co-Chairman, NIH Symposium on Environmental Genome Project, Oct 1997
Co-organizer EPA/NIEHS Workshop on Applying Biomarker Research, Chapel Hill NC, Aug 1999
Co-organizer NIEHS Conference on Epidemiology in the 21st Century, Chapel Hill NC Nov 1999
Co-organizer UNC/NIEHS Conference on Epidemiology of DNA Repair, Chapel Hill, Mar 2001
AACR Annual Meeting, Organizer and Chair, Special Forum on Proteomics, 2004

Invited Talks (selected, since 1994):

American Association for Cancer Research and Environmental Mutagen Society special conference: "Risk Assessment in Environmental Carcinogenesis" Whistler, Canada 1994.

Karolinska Institute, conference: "Molecular Mechanisms of Environmental Mutagenesis and Carcinogenesis" Huddinge, Sweden 1994.

Mayo Clinic Comprehensive Cancer Center, Rochester MN 1994

University of Minnesota Cancer Center, Minneapolis MN 1994

International Society for Environmental Epidemiology Annual Meeting, Symposium: "Genetic susceptibility to environmental hazards," Research Triangle Park, NC 1994.

Agency for Toxic Substances and Disease Registry workshop: "The role of biomarkers in field studies of environmentally associated cancers" Atlanta, GA 1994.

American Association for Cancer Research Annual Meeting, Symposium: "Mechanistic basis of ethnic differences in cancer risk" Toronto, Ontario, Canada 1995

International Society for Environmental Epidemiology Conference: "Host Factors in Environmental Epidemiology". Keynote Address. Cracow Poland 1995

Karolinska Institute Symposium "Molecular mechanisms of environmental mutagenesis and carcinogenesis" Stockholm, Sweden, September 1996

Fred Hutchinson Cancer Research Center and National Cancer Institute Workshop on Diet/Nutrition and Genetic Susceptibility in Relation to Cancer. Washington DC, Jan. 1997

MD Anderson Cancer Center, Grand Rounds, Houston Texas, January 1997

University of California, San Francisco Symposium: "Molecular Advances in Cancer Epidemiology and Prevention. San Francisco February 1997

NIH Director's Seminar Series, Bethesda, March 1997

Society of Toxicology Annual Meeting, Seattle Washington, March 1998

Environmental Mutagen Society Annual Meeting, Plenary Address (Alexander Hollaender Lecture) Anaheim CA, March 1998

University of Cincinnati, Center for Environmental Genetics April 1998

Centers for Disease Control, Conference on Genetics and Public Health, Atlanta GA, May 1998

American College of Epidemiology Workshop on Genetic Fundamentals of Molecular Epidemiology, Chicago IL June 1998; San Francisco CA Sept 1998

12th International Conference on Carcinogenesis and Risk Assessment. Austin TX, Dec 1998

American Cancer Society 2nd Annual Schilling Conference. Santa Cruz CA, March 1999

Society of Toxicology, Chicago IL, May 1999

VII CEPH Annual Conference on Human Genetics; Paris France, May 1999

American College of Epidemiology Workshops, Baltimore June 1999; & Washington DC Oct 1999

NIOSH Workshop on Genetic Susceptibility, Morgantown WV March 2000

American College of Epidemiology Workshops, Seattle June 2000; Atlanta Sept 2000

Invited Talks (selected, since 1994), continued

Norway National Institute of Public Health Conference on Merging Genetics and Epidemiology, Keynote address, Oslo Norway, Aug 2000

American College of Epidemiology Workshops, Toronto Canada, June 2001

Congress of Epidemiology, Toronto Canada, June 2001

US-European Workshop on Gene-Environment Research at the Interface of Toxicology and Epidemiology, Garmisch, Germany Sept 2001

Brown University, Biomedical Center, Providence RI, Nov 2001

Centers for Disease Control, Atlanta GA, Feb 2002

American College of Epidemiology Workshops, Albuquerque Sept 2002

DNA Repair Interest Group National Videoconference, Jan 2003

American College of Epidemiology Workshop, Atlanta GA, June 2003

Environmental Protection Agency, RTP Sept 2003

Centers for Disease Control, Atlanta GA, Sept 2003

Carleton College, Northfield MN, Feb 2004

American Association for Cancer Research Annual Meeting, Orlando FL March 2004

Jackson Laboratory Meeting: "Assessing Human Germ Cell Mutagenesis" Bar Harbor ME Sept 2004

University of North Carolina Center for Environmental Health and Susceptibility, Feb 2005

American Association for Cancer Research Annual Meeting, Anaheim CA, April 2005

Society for Epidemiologic Research Annual Meeting, Toronto, June 2005